Get the Stockscreener App
1.735
1.17%
0.025
Omniab Inc stock is traded at $1.735, with a volume of 217.93K.
It is up +1.17% in the last 24 hours and up +7.45% over the past month.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
See More
Previous Close:
$1.71
Open:
$1.72
24h Volume:
217.93K
Relative Volume:
0.42
Market Cap:
$249.76M
Revenue:
$34.16M
Net Income/Loss:
$-50.62M
P/E Ratio:
-3.4154
EPS:
-0.508
Net Cash Flow:
$703.00K
1W Performance:
-4.95%
1M Performance:
+7.45%
6M Performance:
-2.26%
1Y Performance:
-57.39%
1-Day Range:
$1.708
$1.795
1-Week Range:
$1.59
$1.855
52-Week Range:
$1.22
$4.87
Omniab Inc Stock (OABI) Company Profile
Name
Omniab Inc
Sector
Industry
Phone
510-250-7800
Address
5980 HORTON STREET, EMERYVILLE
Compare OABI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OABI
Omniab Inc
|
1.735 | 231.77M | 34.16M | -50.62M | 703.00K | -0.508 |
|
VRTX
Vertex Pharmaceuticals Inc
|
409.45 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
485.95 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.22 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
830.97 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.32 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Omniab Inc Stock (OABI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-29-23 | Initiated | RBC Capital Mkts | Outperform |
| Apr-21-23 | Initiated | The Benchmark Company | Buy |
| Apr-13-23 | Initiated | Craig Hallum | Buy |
| Feb-22-23 | Initiated | Cowen | Outperform |
| Feb-13-23 | Initiated | H.C. Wainwright | Buy |
| Dec-20-22 | Initiated | Truist | Buy |
| Dec-16-22 | Initiated | Credit Suisse | Outperform |
| Nov-29-22 | Initiated | SVB Leerink | Outperform |
| Nov-28-22 | Initiated | Stifel | Buy |
View All
Omniab Inc Stock (OABI) Latest News
Will OmniAb Inc. stock continue dividend increasesJuly 2025 Chart Watch & High Accuracy Investment Entry Signals - newser.com
Using data models to predict OmniAb Inc. Equity Warrant stock movementJuly 2025 Summary & Free Technical Confirmation Trade Alerts - newser.com
What momentum shifts mean for OmniAb Inc. Equity Warrant2025 Price Action Summary & Risk Adjusted Buy/Sell Alerts - newser.com
Applying Elliott Wave Theory to OmniAb Inc. Equity WarrantQuarterly Trade Report & AI Forecasted Entry and Exit Points - newser.com
Signal strength of OmniAb Inc. stock in tech scanners2025 Valuation Update & Advanced Technical Analysis Signals - newser.com
Quantitative breakdown of OmniAb Inc. recent moveDip Buying & Fast Momentum Stock Entry Tips - newser.com
Will OmniAb Inc. Equity Warrant stock deliver consistent dividendsJuly 2025 Reactions & Free Daily Entry Point Trade Alerts - newser.com
Automated trading signals detected on OmniAb Inc.Weekly Trend Recap & Free Technical Pattern Based Buy Signals - newser.com
Published on: 2025-10-15 04:35:34 - newser.com
Evaluating OmniAb Inc. Equity Warrant with trendline analysisJuly 2025 Movers & Safe Capital Growth Trade Ideas - newser.com
OmniAb (NASDAQ:OABI) Receives Sell (E+) Rating from Weiss Ratings - Defense World
Does OmniAb Inc. show high probability of reboundWeekly Risk Report & Trade Opportunity Analysis Reports - newser.com
OmniAb to Report Third Quarter 2025 Financial Results on November 4 - PharmiWeb.com
How OmniAb Inc. stock compares to industry benchmarksQuarterly Market Summary & Reliable Price Action Trade Plans - newser.com
Technical analysis overview for OmniAb Inc. stock2025 Trading Recap & Technical Entry and Exit Alerts - newser.com
Risk vs reward if holding onto OmniAb Inc. Equity Warrant2025 Trading Volume Trends & Fast Moving Trade Plans - newser.com
Will OmniAb Inc. stock go up soonSell Signal & AI Powered Market Entry Strategies - newser.com
Can swing trading help recover from OmniAb Inc. lossesJuly 2025 Update & Daily Chart Pattern Signals - newser.com
Live market analysis of OmniAb Inc.Volume Spike & Precise Buy Zone Identification - newser.com
OmniAb, Inc. (NASDAQ:OABI) Not Lagging Industry On Growth Or Pricing - simplywall.st
What institutional flow reveals about OmniAb Inc.Earnings Growth Report & Low Risk Entry Point Guides - newser.com
Can Filatex India Limited Stock Sustain Its Uptrend in a Bear MarketBreakout Stock Watch & Low Cost Investment Portfolio - earlytimes.in
OmniAb Inc. Equity Warrant stock trend outlook and recovery pathJuly 2025 Momentum & Reliable Intraday Trade Alerts - newser.com
Using Bollinger Bands to evaluate OmniAb Inc.Trade Volume Summary & High Win Rate Trade Alerts - newser.com
Understanding OmniAb Inc.’s price movementTrade Risk Report & Risk Controlled Daily Plans - newser.com
Is OmniAb Inc Equity Warrant a good long term investmentTake Profit Strategies & Minimize Portfolio Damage with Warnings - earlytimes.in
Comparing Astellas Pharma (OTCMKTS:ALPMY) and OmniAb (NASDAQ:OABI) - Defense World
Public Employees Retirement System of Ohio Makes New Investment in OmniAb, Inc. $OABI - Defense World
Will OmniAb Inc. Equity Warrant stock outperform value stocksPortfolio Return Summary & AI Powered Trade Plan Recommendations - newser.com
Omniab Inc Stock (OABI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Omniab Inc Stock (OABI) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Love Steven | Director |
May 14 '25 |
Buy |
1.46 |
25,000 |
36,500 |
38,333 |
| HIGGINS JOHN L | Director |
May 12 '25 |
Buy |
1.44 |
65,000 |
93,600 |
2,831,887 |
| FOEHR MATTHEW W | President and CEO |
Apr 07 '25 |
Option Exercise |
0.00 |
36,458 |
0 |
3,815,618 |
| FOEHR MATTHEW W | President and CEO |
Apr 07 '25 |
Sale |
2.00 |
19,382 |
38,764 |
3,796,236 |
| Berkman Charles S | Chief Legal Officer |
Apr 07 '25 |
Option Exercise |
0.00 |
13,542 |
0 |
370,418 |
| Berkman Charles S | Chief Legal Officer |
Apr 07 '25 |
Sale |
2.00 |
7,206 |
14,412 |
363,212 |
| GUSTAFSON KURT A | Executive VP, Finance and CFO |
Apr 07 '25 |
Option Exercise |
0.00 |
13,542 |
0 |
231,034 |
| GUSTAFSON KURT A | Executive VP, Finance and CFO |
Apr 07 '25 |
Sale |
2.00 |
7,206 |
14,412 |
223,828 |
3.22%
1.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):